Maloca, Peter M.
Zarranz-Ventura, Javier
Valmaggia, Philippe
Faludi, Balázs
Zelechowski, Marek
Tufail, Adnan
Zentai, Norbert Z.
Scholl, Hendrik P. N.
Cattin, Philippe C.
Article History
Received: 18 February 2023
Accepted: 19 June 2023
First Online: 21 June 2023
Competing interests
: P.C.C. is the owner of the proposed software. P.C.C. is the owner of the proposed software. P.C.C, B.F. and M.Z. are inventors and owners of the described software and shareholders in the company Specto Medical. The other authors declare no conflict. Outside of the present study, the authors declare the following competing interests: P.M.M. is a consultant at Roche (Basel, Switzerland), Zeiss Forum, and holds intellectual property for machine learning at MIMO AG and VisionAI, Switzerland. P.V. received funding from the Swiss National Science Foundation (Grant 323530_199395) and the Janggen-Pöhn Foundation. J.Z.V. has been a consultant from Alcon, Alimera Science, Allergan, Bausch & Lomb, Bayer, Brill Pharma, DORC, Novartis, and Roche; is a grant holder in Allergan and Novartis; and has been a lecturer for Topcon and Zeiss. H.P.N.S. is supported by the Swiss National Science Foundation (Project funding: “Developing novel outcomes for clinical trials in Stargardt disease using structure/function relationship and deep learning” #310030_201165, and National Center of Competence in Research Molecular Systems Engineering: “NCCR MSE: Molecular Systems Engineering (phase II)” #51NF40-182895), the Wellcome Trust (PINNACLE study), and the Foundation Fighting Blindness Clinical Research Institute (ProgStar study). Dr. Scholl is member of the Scientific Advisory Board of: Boehringer Ingelheim Pharma GmbH & Co; Claris Biotherapeutics Inc.; Eluminex Biosciences; Gyroscope Therapeutics Ltd.; Janssen Research & Development, LLC (Johnson & Johnson); Novartis Pharma AG (CORE); Okuvision GmbH; ReVision Therapeutics Inc.; and Saliogen Therapeutics Inc. Dr. Scholl is a consultant of: Alnylam Pharmaceuticals Inc.; Gerson Lehrman Group Inc.; Guidepoint Global, LLC; and Intergalactic Therapeutics Inc. Dr. Scholl is member of the Data Monitoring and Safety Board/Committee of Belite Bio (CT2019-CTN-04690–1), F. Hoffmann-La Roche Ltd (VELODROME trial, NCT04657289; DIAGRID trial, NCT05126966; HUTONG trial) and member of the Steering Committee of Novo Nordisk (FOCUS trial; NCT03811561). All arrangements have been reviewed and approved by the University of Basel (Universitätsspital Basel, USB) and the Board of Directors of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) in accordance with their conflict of interest policies. Compensation is being negotiated and administered as grants by USB which receives them on its proper accounts. Dr. Scholl is co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) which is constituted as a non-profit foundation and receives funding from the University of Basel, the University Hospital Basel, Novartis, and the government of Basel-Stadt. Alphabetical List:Alnylam Pharmaceuticals Inc., Belite Bio, Boehringer Ingelheim Pharma GmbH & Co, Claris Biotherapeutics Inc., Eluminex Biosciences, F. Hoffmann-La Roche Ltd, Gerson Lehrman Group Inc., Guidepoint Global, LLC, Gyroscope Therapeutics Ltd, Intergalactic Therapeutics Inc., Janssen Research & Development, LLC (Johnson & Johnson), Novartis Pharma AG (CORE), Novo Nordisk, Okuvision GmbH, ReVision Therapeutics Inc., Saliogen Therapeutics Inc. A.T. received funding from Novartis and a financial grant from the National Institute for Health Research (NIHR) Biomedical Research Centre, based at Moorfields Eye Hospital, and also from the NHS Foundation Trust and the UCL Institute of Ophthalmology. A.T. is a consultant for Heidelberg Engineering and Optovue and has received research grant funding from Novartis and Bayer.